AbbVie has launched a phase III trial of its poly ADP ribose polymerase (PARP) inhibitor veliparib (ABT-888) for patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer. The trial will compare patients randomized to receive carboplatin and paclitaxel with veliparib against patients receiving carboplatin and paclitaxel with a placebo. The primary endpoint is overall survival. The global, multicenter trial will recruit approximately 900 patients.
For more information on eligibility and sites, see this listing.